This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.1 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Hemophilia C, Rosenthal syndrome, Hereditary factor XI deficiency, PTA deficiency, Factor XI deficiency |
| C. Adult onset | Likelihood of first onset in adulthood: very high — spontaneous bleeding is rare and the diagnosis is often made only after invasive procedures such as surgery or tooth extraction, so cases first discovered in adulthood are common |
| 1. History | History of the international scholarly discussion before and after Rosenthal named PTA in 1952, up to confirmation of its identity with FXI |
| 2. Causes | Decreased plasma concentration or abnormal function of coagulation factor XI due to F11 gene variants |
| 3. Genetics | F11 gene located at 4q35.2, autosomal recessive inheritance, Ashkenazi Jewish founder variants |
| 4. Epidemiology | 1 per million in the general population; carrier frequency of about 8% among Ashkenazi Jews |
| 5. Pathophysiology | Role of FXI in the intrinsic coagulation pathway and the thrombin amplification loop |
| 6. Symptoms | Bleeding after surgery or trauma, epistaxis, hematuria; spontaneous joint bleeding is rare |
| 7. Signs | Isolated APTT prolongation, decreased FXI activity, normal PT |
| 8. Screening | Recognition of the pattern of prolonged APTT + normal PT |
| 9. Diagnosis | Measurement of FXI activity, F11 gene analysis |
| 10. Treatment | Fresh frozen plasma, FXI concentrate, tranexamic acid |
| 11. Prognosis | Normal life is possible with appropriate management; nonlinear relationship between bleeding risk and FXI level |
| 12. Prevention | Preoperative prophylactic plasma administration, genetic counseling |
| 13. References | Rosenthal RL et al. (1953) Blood … and 11 other papers |
The name Plasma Thromboplastin Antecedent (PTA) is known to have been first publicly proposed by the American hematologist Robert L. Rosenthal at an international scientific meeting in 1952. However, its conceptual background was formed in scholarly discussions at least a year earlier. At the 1951 annual meeting of the American Society of Hematology (ASH), Rosenthal's group presented preliminary data suggesting the existence of a new plasma coagulation factor, and in 1952 reported further details of its characteristics to the society.
At the time, coagulation researchers were focusing on the fact that cross-mixing normal serum and normal plasma corrected the clotting time of certain hemophilia patients. However, the families of the 3 patients studied by Rosenthal had neither classic hemophilia A (FVIII deficiency) nor B (FIX deficiency), but a third type. This third type was PTA deficiency, and it showed a unique cross-correction pattern that was not corrected by either normal serum or adsorbed plasma.
In 1953, Rosenthal published a paper in the journal Blood under the names of his colleague Dreskin and Rosenthal, titled "A new hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor". In this paper, the new factor was named PTA, meaning 'a substance antecedent to the formation of plasma thromboplastin'. Rosenthal described that this factor is present in serum and absent from adsorbed plasma, which allows it to be distinguished from FIX (PTC, plasma thromboplastin component).
Around the same time in the United Kingdom, this disease began to be called 'Hemophilia C', meaning the third type after hemophilia A and B. The name 'Rosenthal syndrome' was also used in some literature, after the person who proposed it. This confusion of one disease being called by several names was resolved in the 1960s when the international committee on the nomenclature of coagulation factors introduced the Roman numeral system, and PTA was officially designated coagulation factor XI (Factor XI, FXI).
In 1960, when the Roman numeral nomenclature system for coagulation factors was agreed upon at a scientific meeting of the predecessor of the International Society on Thrombosis and Haemostasis (ISTH), PTA was officially replaced by Factor XI (FXI). However, the historical names 'PTA deficiency' or 'plasma thromboplastin antecedent deficiency' still remain in the ICD coding system and some Korean Special Copayment Reduction documents. This stems from ICD-10 code D68.1 encompassing this concept.
With advances in molecular biology in the 1990s, the F11 gene was found to be located on chromosome 4q35.2, and specific founder mutations were confirmed to exist at high frequency in the Ashkenazi Jewish population. Subsequently, FXI was shown to play a key role in the thrombin generation amplification loop, beyond being a simple 'intrinsic pathway factor', and research on developing anticoagulants targeting it has been actively under way since the 2010s.
The direct cause of plasma thromboplastin antecedent deficiency, i.e., FXI deficiency, is pathogenic variants in the F11 gene. The F11 gene is located on chromosome 4q35.2 and consists of 15 exons in total. Various types of variants arising in this gene, such as missense variants, nonsense variants, splicing variants, and small deletions/insertions, cause decreased synthesis or abnormal function of the FXI protein.
It is clinically important that the severity of FXI deficiency is not necessarily proportional to genotype. Some patients have no severe spontaneous bleeding even with very low serum FXI activity levels, while others develop serious postoperative bleeding even at relatively high activity levels. This is because the contribution of FXI to clot formation varies with the tissue site where it acts, and the bleeding risk is especially prominent in the oral, nasal, and genitourinary mucosa, where fibrinolytic activity is high.
Besides congenital (hereditary) forms, FXI deficiency can also be acquired. The most important acquired cause is the formation of autoantibodies (inhibitors) against FXI, which is associated with autoimmune diseases (systemic lupus erythematosus, etc.), malignancies, and the use of certain drugs. FXI levels may also be secondarily reduced in liver disease, vitamin K deficiency, and disseminated intravascular coagulation (DIC). Because 'plasma thromboplastin antecedent deficiency' covered by Special Copayment Reduction V009 refers to congenital hereditary deficiency, excluding these acquired causes first is the starting point of diagnosis.
The F11 gene is located on human chromosome 4q35.2 and spans about 23 kb. Consisting of 15 exons, this gene encodes the FXI protein, made up of 607 amino acids. The FXI protein exists in plasma as a homodimer and circulates as a serine protease precursor (zymogen). Each monomer consists of 4 Apple domains and 1 catalytic domain.
FXI deficiency is inherited in an autosomal recessive manner, and heterozygotes are usually mildly affected or asymptomatic. Severe deficiency appears in homozygotes and compound heterozygotes. More than 200 pathogenic variants in the F11 gene have been reported to date, but in the Ashkenazi Jewish population two founder variants, the Type II variant (p.Glu117Stop) and the Type III variant (p.Phe283Leu), account for most mutations. Compound heterozygosity for these two variants is the most common cause of severe FXI deficiency among Ashkenazi Jews.
Population-specific founder variants have also been reported in people of Japanese, Iranian, and Arab descent, and in Koreans there are sporadic case reports of F11 variants, although rare. FXI activity in heterozygotes is generally around 50% of normal, in which case the risk of postoperative bleeding may be mildly increased.
FXI deficiency (plasma thromboplastin antecedent deficiency) is a rare bleeding disorder occurring at a frequency of about 1 per million in the general population. However, this figure is limited to severe deficiency, and the actual frequency is much higher when mild heterozygous states are included. Among Ashkenazi Jews, severe deficiency due to homozygosity or compound heterozygosity is reported at about 0.1–0.3% and mild heterozygous deficiency at about 8%, making the prevalence in this population the highest in the world.
In Korea, there is no separate nationwide registration system for FXI deficiency, so accurate prevalence statistics are lacking. The number of patients registered under D68.1 in Health Insurance Review & Assessment Service (HIRA) Special Copayment Reduction data is very small, and many are presumed to have been discovered incidentally on preoperative testing. It occurs equally in males and females (autosomal inheritance) and is not concentrated in any particular age group. Considering that adult patients first discovered by preoperative APTT prolongation are not uncommon in clinical practice, the actual prevalence is likely higher than the number registered.
In the traditional coagulation cascade model, FXI is a component of the intrinsic pathway, activated by activated FXII (FXIIa) and responsible for generating FIXa. However, according to the modern cell-based model of coagulation, FXI functions mainly through feedback activation by thrombin (thrombin-back activation). That is, once a small initial amount of thrombin is generated by the tissue factor pathway (extrinsic pathway), this thrombin in turn activates FXI, operating a loop that amplifies FIX → FX → thrombin generation.
This amplification loop is especially important in mucosal tissues with high fibrinolytic activity (oral cavity, genitourinary tract, etc.). At these sites, initial clots are rapidly lysed, so sufficient thrombin generation is essential, and in FXI deficiency this amplification loop is weakened, making hemostasis incomplete. In contrast, at sites with low fibrinolytic activity such as the musculoskeletal system, adequate hemostasis can be achieved even without FXI, which explains why spontaneous joint bleeding is rare in patients with FXI deficiency.
Paradoxically, FXI has recently drawn attention as a new target for thrombosis prevention. Epidemiological observations have accumulated that patients with FXI deficiency rarely experience deep vein thrombosis or pulmonary embolism, and on this basis FXI inhibitors (antisense oligonucleotides, small-molecule inhibitors, monoclonal antibodies, etc.) are in clinical development. This reflects the concept that FXI contributes mainly to pathological thrombus formation while being less involved in physiological hemostasis, and it is a case in which research on the pathophysiology of FXI deficiency led directly to the development of new antithrombotic drugs.
The most characteristic clinical symptom of FXI deficiency is excessive bleeding after invasive procedures such as surgery, tooth extraction (dental procedures), and childbirth. Unlike hemophilia A or B, spontaneous joint bleeding (hemarthrosis) and intramuscular hematomas are rare, and bleeding occurs mainly at procedure sites associated with mucosal tissue. Cases have been reported in which bleeding after tooth extraction persists for hours to days, or severe bleeding after tonsillectomy requires reoperation.
Some patients with severe FXI deficiency have recurrent nosebleeds (epistaxis), hematuria, and menorrhagia. In particular, the genitourinary and oral mucosa are rich in fibrinolytic enzymes (t-PA, etc.) and are therefore more strongly affected by FXI deficiency. In female patients, menorrhagia can be a symptom that greatly impairs quality of life, and the risk of postpartum hemorrhage during childbirth is also increased. Intracranial hemorrhage is very rare, reflecting the relatively mild clinical course of FXI deficiency compared with hemophilia A/B.
The relationship between FXI activity level and bleeding tendency is nonlinear. Patients with severe deficiency, with FXI activity below 1% of normal, may not bleed at all without surgery, whereas some patients with mild deficiency of 20–30% experience serious bleeding after tooth extraction. This unpredictability makes bleeding risk assessment difficult and suggests that treatment decisions are hard to make based on baseline FXI activity alone. A personal and family history of bleeding is as important as, or more important than, the FXI level in establishing a treatment strategy.
The most characteristic laboratory finding of FXI deficiency is isolated prolongation of the activated partial thromboplastin time (APTT). The prothrombin time (PT) and thrombin time (TT) are within the normal range, suggesting an abnormality of the intrinsic pathway. The degree of APTT prolongation is somewhat proportional to the severity of FXI deficiency, but results may vary with differences in reagents between laboratories and the type of coagulation analyzer.
For confirmation and severity classification, the FXI one-stage clotting assay is performed. Criteria commonly used classify FXI activity below 20% of normal as severe, 20–70% as intermediate, and 70% or more as mild. When an inhibitor is suspected, a mixing study is performed, and failure of the APTT to correct after 1:1 mixing suggests the presence of an inhibitor. In this case, measurement of the FXI-specific inhibitor titer (Bethesda assay) is additionally needed.
On routine preoperative coagulation testing, the pattern of isolated APTT prolongation with normal PT requires differentiation among deficiencies of intrinsic pathway factors (FVIII, FIX, FXI, FXII), lupus anticoagulant (LA), heparin contamination, etc. Because hemophilia A (FVIII deficiency) and B (FIX deficiency) are more common, it is usual to exclude them first. FXII deficiency is distinguished from FXI deficiency in that the APTT is markedly prolonged but there are no bleeding symptoms.
The APTT often exceeds the upper limit of normal only when FXI activity falls below 15–30%, so false negatives can occur in mild deficiency. In addition, pregnancy, inflammation, and estrogen administration raise FXI levels and can temporarily mask the deficiency. Considering these physiological variations, directly measuring FXI activity in patients with a history of bleeding is a clinically reasonable approach even if the APTT is normal.
The diagnosis of FXI deficiency is made in stages. In step 1, coagulation screening tests (PT, APTT, TT, platelet count) are performed and isolated APTT prolongation is confirmed. In step 2, an FXI one-stage activity assay is performed to quantify the FXI level. In step 3, if necessary, F11 gene variants are identified through molecular genetic testing. Molecular genetic testing is recommended for genetic counseling, prenatal diagnosis, family screening, and especially for confirming founder variants in patients of Ashkenazi Jewish descent.
Pathogenic variants can be identified through Sanger sequencing of the F11 gene or a next-generation sequencing (NGS)-based coagulation panel. In particular, confirming homozygosity or compound heterozygosity is essential for determining the inheritance pattern and assessing risk within the family. When an inhibitor is present, this suggests acquired FXI deficiency rather than hereditary deficiency, so a separate search for an underlying disease is needed.
The basis of treatment for FXI deficiency is administration of fresh frozen plasma (FFP). FFP supplies all coagulation factors, including FXI, and is used for preoperative prophylaxis or to treat bleeding. Generally, 15–20 mL/kg of FFP can raise the FXI level to 30–45%. In some countries, FXI concentrate (factor XI concentrate) is approved (e.g., France, United Kingdom), but in Korea there is not yet an approved FXI concentrate, so accessibility in clinical practice is limited.
Tranexamic acid is an antifibrinolytic agent that is useful as an adjunct, particularly in FXI-deficient patients with prominent mucosal bleeding. It is given alone or in combination with FFP for oral procedures, tooth extraction, and control of menorrhagia. Oral contraceptives or the levonorgestrel intrauterine system (LNG-IUS) effectively reduce bleeding in female FXI-deficient patients with menorrhagia. Desmopressin (DDAVP) is sometimes tried in special situations, but evidence of its efficacy in FXI deficiency is limited.
In patients who have developed FXI inhibitors, hemostasis may not be achieved with usual FFP administration. In this case, recombinant activated FVII (rFVIIa, NovoSeven) can be used as bypassing therapy. In the long term, immunosuppressive treatment (prednisolone, rituximab, etc.) to eliminate the inhibitor is considered.
FXI deficiency has a relatively milder bleeding tendency than hemophilia A or B, so with appropriate preventive measures and bleeding management, a normal life expectancy and social activity are possible. Because arthropathy due to spontaneous joint bleeding rarely develops, the risk of long-term disability is markedly lower than in hemophilia A/B. Most causes of death are related to accompanying underlying diseases or aging rather than to bleeding itself.
The most important factor affecting prognosis is the thoroughness of preoperative preventive measures. If the FXI level is not raised to the target (generally 45% or more) before surgery or invasive procedures, serious bleeding complications may occur. In this case, reoperation, transfusion, and intensive care unit admission become necessary, greatly increasing morbidity. Education of patients and surgical teams and a system of collaboration with coagulation specialists are decisive for improving prognosis.
In patients with FXI deficiency, a prior evaluation by a coagulation specialist must be carried out before planned surgery or invasive procedures. For major surgery, FFP (15–20 mL/kg) is given immediately before surgery to raise the FXI level to 45% or more, with additional doses for several days after surgery if needed. When the risk of mucosal bleeding is high, as in oral and maxillofacial surgery or urological procedures, perioperative co-administration of tranexamic acid is recommended.
Genetic counseling and screening of the families of patients with FXI deficiency, especially siblings and children, are very important for prevention. Even asymptomatic heterozygous carriers may need measurement of FXI levels and advance planning before major surgery. In people of Ashkenazi Jewish descent, targeted genetic testing for the Type II and Type III founder variants is a cost-effective screening method. Female patients of reproductive age should establish a plan to prevent bleeding at delivery in advance through obstetrics-hematology consultation before planning pregnancy and childbirth.